SCHEMBL19851229

SCHEMBL19851229

CCC(CC)C1CC(=O)NC1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 1/20 0.40
CRBN Q96SW2 1/20 0.38
NPC1 O15118 3/20 0.36
GLA P06280 1/20 0.34
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
RAB9A P51151 3/20 0.32
CYP19A1 P11511 1/20 0.32
SMN1; SMN2 Q16637 4/20 0.31
LMNA P02545 4/20 0.31
ALDH1A1 P00352 3/20 0.31
NR2F2 P24468 2/20 0.31
HIF1A Q16665 2/20 0.31
HTT P42858 2/20 0.31
CYP2C19 P33261 2/20 0.31
CYP1A2 P05177 1/20 0.31
MAPK1 P28482 1/20 0.31
TP53 P04637 1/20 0.31
CYP3A4 P08684 1/20 0.31
SLC2A1 P11166 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27292935 0.89 NPC1 (0.36) MAP3K14CRBNNPC1GLAALDH1A1
SCHEMBL18888511 0.86 NPC1 (0.40) MAP3K14CRBNNPC1GLALMNA
SCHEMBL5617171 0.84 NPC1 (0.39) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL4455145 0.83 ALDH1A1 (0.40) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL19657857 0.83 ALDH1A1 (0.40) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL9569047 0.83 ALDH1A1 (0.40) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL18473550 0.83 ALDH1A1 (0.40) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL6077509 0.83 ALDH1A1 (0.40) MAP3K14CRBNNPC1LMNAALDH1A1
SCHEMBL755754 0.82 MAP3K14 (0.39) MAP3K14CRBNNPC1GLABRD4
SCHEMBL22394491 0.80 MAP3K14 (0.38) MAP3K14CRBNNPC1GLABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023178641-A1 DNA TOXIC DIMER COMPOUND AND CONJUGATE THEREOF 成都百利多特生物药业有限责任公司 2023-09-28 WO disclosed
US-20180036421-A1 METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES ABBVIE STEMCENTRX LLC (US) 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180036421-A1 METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES DLK1, MCL1, LANCL1 MAP3K14 2989/4885CRBN 364/4885NPC1 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.